Protective efficacy afforded by live Pasteurella multocida vaccines in chickens is independent of lipopolysaccharide outer core structure |
| |
| Affiliation: | 1. Clinical Bacteriology Laboratory, Indian Veterinary Research Institute (IVRI), Mukteswar-263138, Nainital (District), Uttarakhand (UK), India;2. National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI), Bengaluru-560024, Karnataka, India;3. Division of Bacteriology and Mycology, Indian Veterinary Research Institute (IVRI), Izatnagar-243122, Uttar Pradesh (UP), India;4. Division of Virology, Indian Veterinary Research Institute (IVRI), Mukteswar-263138, Nainital (District), Uttarakhand (UK), India;1. Department of Biology, Faculty of Science, Çankırı Karatekin University, 18100 Çankırı, Turkey;2. Enzyme and Microbial Biotechnology Section, Department of Agricultural Biotechnology, Faculty of Agriculture, Ondokuz Mayıs University, 55139 Samsun, Turkey;1. Clinical Bacteriology Laboratory, Indian Veterinary Research Institute (IVRI), Mukteswar-263138, Nainital, Uttarakhand, India;2. National Institute of Veterinary Epidemiology and Disease Informatics (NIVEDI), Bengaluru-560024, Karnataka, India;3. Division of Bacteriology and Mycology, Indian Veterinary Research Institute (IVRI), Izatnagar-243122, Bareilly, Uttar Pradesh, India |
| |
| Abstract: | Pasteurella multocida is a major animal pathogen that causes a range of diseases including fowl cholera. P. multocida infections result in considerable losses to layer and breeder flocks in poultry industries worldwide. Both killed whole-cell and live-attenuated vaccines are available; these vaccines vary in their protective efficacy, particularly against heterologous strains. Moreover, until recently there was no knowledge of P. multocida LPS genetics and structure to determine precisely how LPS structure affects the protective capacity of these vaccines. In this study we show that defined lipopolysaccharide (LPS) mutants presented as killed whole-cell vaccines elicited solid protective immunity only against P. multocida challenge strains expressing highly similar or identical LPS structures. This finding indicates that vaccination of commercial flocks with P. multocida killed cell formulations will not protect against strains producing an LPS structure different to that produced by strains included in the vaccine formulation. Conversely, protective immunity conferred by vaccination with live P. multocida strains was found to be largely independent of LPS structure. Birds vaccinated with a range of live mutants belonging to the L1 and L3 LPS genotypes, each expressing a specific truncated LPS structure, were protected against challenge with the parent strain. Moreover, birds vaccinated with any of the five LPS mutants belonging to the L1 LPS genotype were also protected against challenge with an unrelated strain and two of the five groups vaccinated with live LPS mutants belonging to the L3 genotype were protected against challenge with an unrelated strain. In summary, vaccination with live P. multocida aroA mutants producing full-length L1 or L3 LPS or vaccination with live strains producing shortened L1 LPS elicited strong protective immunity against both homologous and heterologous challenge. |
| |
| Keywords: | Vaccine Lipopolysaccharide |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
